Cited by

• Phorbol ester-induced enhancement in lytic activity of CD8+ splenic T cells from low-dose melphalan-treated MOPC-315-tumor bearers.

  Weiskirch LM, Baumgartel BA, Barker E, Mokyr MB. Weiskirch LM, et al. Cancer Immunol Immunother. 1991;32(6):353-63. doi: 10.1007/BF01741330. Cancer Immunol Immunother. 1991. PMID: 1901031 Free PMC article.
• In vitro induction of tumor-specific immunity. I. Parameters of activation and cytotoxic reactivity of mouse lymphoid cells immunized in vitro against syngeneic and allogeneic plasma cell tumors.

  Wagner H, Röllinghoff M. Wagner H, et al. J Exp Med. 1973 Jul 1;138(1):1-15. doi: 10.1084/jem.138.1.1. J Exp Med. 1973. PMID: 4541509 Free PMC article.
• Characterization of the exogenous interleukin-2 requirements for the generation of enhanced antitumor cytotoxicity by thymocytes from low-dose melphalan-treated MOPC-315 tumor bearers.

  Rubin M, Mokyr MB. Rubin M, et al. Cancer Immunol Immunother. 1993;36(1):37-44. doi: 10.1007/BF01789129. Cancer Immunol Immunother. 1993. PMID: 8422666 Free PMC article.
• Melphalan-mediated potentiation of antitumor immune responsiveness of immunosuppressed spleen cells from mice bearing a large MOPC-315 tumor.

  Bocian RC, Ben-Efraim S, Dray S, Mokyr MB. Bocian RC, et al. Cancer Immunol Immunother. 1984;18(1):41-8. doi: 10.1007/BF00205398. Cancer Immunol Immunother. 1984. PMID: 6435857 Free PMC article.
• Neurotransmitter suppression of the in vitro generation of a cytotoxic T lymphocyte response against the syngeneic MOPC-315 plasmacytoma.

  Cook-Mills JM, Mokyr MB, Cohen RL, Perlman RL, Chambers DA. Cook-Mills JM, et al. Cancer Immunol Immunother. 1995 Feb;40(2):79-87. doi: 10.1007/BF01520288. Cancer Immunol Immunother. 1995. PMID: 7882386 Free PMC article.